Retatrutide 8mg

$80.00

Retatrutide is not currently approved by the FDA for any indication.
It is still in the clinical trial phase, with Phase 3 trials ongoing.
Topline results from the Phase 3 trials are expected in late 2025, with potential FDA submission in 2026 and retail availability possible in 2027.

Category: RETATRUTIDES

Description
Reviews (0)

Retatrutide is an investigational drug being developed by Eli Lilly for weight loss and other metabolic conditions.

Here’s some information about Retatrutide:

Dosage information

The 8mg dosage of Retatrutide was studied in a Phase 2 clinical trial involving adults with obesity.
Participants were randomized to receive various doses, including those that reached 8 mg once weekly for 48 weeks.
The phase 2 trial findings showed that the average weight loss was approximately 22.8% in the combined 8 mg groups after 48 weeks.

Mechanism of action

Retatrutide is a “triple G” or triple hormone receptor agonist that works by mimicking three hunger-regulating hormones: glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This approach is thought to offer a more potent effect on appetite and food satisfaction compared to medications targeting fewer hormones.

Potential benefits

In addition to significant weight loss, the Phase 2 trial revealed that Retatrutide might offer other health benefits, such as improvements in blood pressure and indicators of blood sugar, including glycated hemoglobin, insulin, and fasting glucose.
It also reduced liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with the 8mg dose leading to an 81.7% decrease in liver fat at 48 weeks.

Side effects

The most commonly reported side effects in the Retatrutide clinical trials were gastrointestinal symptoms like nausea, vomiting, diarrhea, and constipation.
These side effects were typically mild to moderate in severity and were often dose-related, meaning they were more pronounced at higher doses and when the dose was escalated too quickly.

FDA approval status

Retatrutide is not currently approved by the FDA for any indication.
It is still in the clinical trial phase, with Phase 3 trials ongoing.
Topline results from the Phase 3 trials are expected in late 2025, with potential FDA submission in 2026 and retail availability possible in 2027.

Important considerations

Using Retatrutide outside of a clinical trial setting is illegal and potentially dangerous due to the lack of FDA approval and safety oversight.
Beware of compounded or research-grade Retatrutide being sold online, as these products may be of unknown quality and potentially unsafe.

Always consult with a qualified healthcare provider before considering any new weight loss therapy or medication.